Roche-UCB’s $120M collaboration; Omega snags $85M; ExeVir raises $27M; GSK culls pipeline meds after failures
Jul 30, 2020
Roche bets USD 120 Million on UCB’s anti-tau Alzheimer’s antibody The Swiss pharma, Roche, is handing over USD 120 million upfront for the right of UCB’s ...
Read More
Kiadis inks license deal with Sanofi; Gilead Ends Hep B Collaboration; Merck & Foghorn inks $425M deal; Tregs research updates
Jul 9, 2020
Sanofi licenses NK cells of Kiadis to boost the efficacy Sanofi has licensed the natural killer (NK) cells from Kiadis Pharma for use in combination with its multiple...
Read More
Regeneron’s cocktail antibody, REGN-COV2; J&J’s manufacturing-spree; ObsEva’s Yselty top-line studies
Jul 7, 2020
Regeneron Pharmaceuticals launches the Phase III trials of REGN-COV2 for treatment and prevention of COVID-19. Regeneron is running two trials simultaneously, one for pr...
Read More
FDA’s No to Intercept’s NASH Drug; Roche’s Phesgo gets approval; Gilead’s Remdesivir pricing
Jun 30, 2020
Intercept Pharmaceuticals receives a clear rejection from the FDA for its NASH drug, Obeticholic acid (OCA) Intercept Pharmaceuticals announced the issuance of a Complete R...
Read More
Regeneron’s I-O Drug; Gene Therapy for Parkinson’s Disease; Yumanity and Merck Inks $500M Deal; Simcha Raises $25M
Jul 6, 2020
Regeneron recognizes new combos to boost I-O drug Libtayo’s cancer response PD-1/L1 inhibitors work by enhancing the immune response to cancer, have benefitted patien...
Read More
Sarepta & Codiak Inks $72.5M Deal; Invitae to Acquires ArcherDX; Merck announces V114’s Phase III result
Jul 6, 2020
Sarepta Therapeutics has announced a research and option alliance with Codiak BioSciences to design and develop engineered exosome therapeutics for neuromuscular diseases T...
Read More
Lassen’s anti-IL-11 antibody; PTC’s COVID-19 trial; Lenzilumab’s result; Orca raises $192M
Jul 6, 2020
Lassen Therapeutics to create anti-IL-11 antibody for cancer and fibrosis Lassen Therapeutics is revealing USD 31 million from Frazier Healthcare Partners, Alta Venture and...
Read More
Merck supports Peloton Therapeutics; Thermo Fisher, WuXi and Mayo Clinic join hands; JNJ’s anti-BCMA CAR-T sweeps multiple myeloma aside; Tafinlar-Mekinist combo of Novartis receives a boost
May 14, 2020
Merck supports Peloton Therapeutics with positive kidney cancer data Merck is revealing the data from a phase 2 study of a HIF-2α inhibitor after a year betting USD 1.05 b...
Read More
In the fight against COVID-19 – Lilly with Olumiant, Gilead with remdesivir, Rutgers with testing kit
Apr 14, 2020
Eli Lilly has announced to begin clinical trials of rheumatoid arthritis drug Olumiant to treat COVID-19 patients. The company plans to explore the anti-inflammatory ...
Read More
Ofev’s expanded use; Arkin Bio-Ventures II launch; USD 125 M for COVID-19 treatment
Mar 11, 2020
Boehringer Ingelheim’s Ofev (nintedanib) has received FDA recommendation for the treatment of chronic fibrosing interstitial lung diseases (ILD) with a progressive phenot...
Read More
Gilead to buy Forty Seven; Akrevia Therapeutics unveils new identity; FDA approved pyrimethamine
Mar 3, 2020
Gilead Sciences has announced to purchase an Immuno-oncology company Forty Seven for USD 95.50 per share, totalling up to a deal value of USD 4.9 billion. By acquiring Fort...
Read More
Incyte meets endpoint in second atopic dermatitis trial; NeoTX lands USD 45 M series C; Five Prime Therapeutics’ pancreatic cancer a bust
Feb 20, 2020
Incyte meets endpoint in the second pivotal atopic dermatitis clinical trial A second phase 3 trial of Incyte’s ruxolitinib cream in atopic dermatitis has hit its primary...
Read More
Immune cells for age-related diseases; Regeneron’s antibody for 2019-nCoV; FDA nods for hydrogel injection
Feb 6, 2020
Activated immune cells responsible for improving age-related diseases The main culprits of the inflammatory responses associated with asthma are Interleukins IL-33 and IL...
Read More
First-ever Peanut allergy treatment; Dinutuximab misses primary endpoint; Insmed’s shares Soares
Feb 14, 2020
The US FDA has given its recommendation to the Aimmune Therapeutics’ drug, Palforzia, the first-ever treatment for Peanut Allergy. Palforzia is an oral immunotherapy, set...
Read More
Annovis announces IPO results; Conatus merges with Histogen; Novartis discontinues its generic journey
Feb 14, 2020
A Philadelphia-based pharmaceutical, Annovis Bio, has raised USD12 million by listing its 2 million shares at USD 6 each. The company has managed to net USD 2 million more ...
Read More
